Saint Luc Clinical Coordinating Center

image Follow Us:

  • SLUCCC

SLUCCC Physicians

SLUCCC physicians are experts in critical care disease, sepsis and infectious diseases.

Read more

Past & Current Trials

  • A phase Ib/IIb, randomised, double blind, parallel group, placebo, controlled multicentre study to assess the safety and efficacy of expanded Cx611 allogenic adipose-derived stem cells for IV treatment of adult patients with severe community-acquired bacterial pneumonia and admitted to ICU (SEPCELL) / Tigenix / 2016-ongoing
  • Effort to Prevent Nosocomial Pneumonia caused by Pseudomonas aeruginosa in Mechanically Ventilated Subjects (EVADE)/ Medimmune / 2016-ongoing
  • A double-blind, randommised, placebo-controlled, phase IIB/III adaptive clinical trial investigating the efficacy and safety of selepressin as treatment for patients with vasopressor-dependent septic shock (SEPSIS-ACT)/ Ferring pharmaceuticals / 2015-ongoing
  • A Human Monoclonal Antibody Against Staphylococcus aureus Alpha Toxin in Mechanically Ventilated Adult Subjects (SAATELLITE)/ Medimmune / phase II study / 2014-ongoing
  • Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated patients with Gram-negative Bacterial Pneumonia (IASIS) / Cardeas Pharma / 2013-2015
  • Phase III study to assess the safety and efficacy of ART-123 (Recombinant human soluble thrombomodulin) in subjects with severe sepsis and coagulopathy / Asahi Kasei / 2012-ongoing
  • Study to Compare the Efficacy and Safety of Two Dosing Regimens of Intravenous Infusions of CytoFab™ (AZD9773) in Adult Patients With Severe Sepsis and/or Septic Shock / AstraZeneca / 2010-2012
  • Study of the safety and efficacy of the talactoferrin Alpha in patient with severe sepsis (OASIS), phase II and III / Agennix Incorporated / 2010-2012
  • ATryn - Leo 90010-I21: antithrombin alfa in patients with disseminated intravascular coagulation associated with severe sepsis / Leopharma / 2007-2008
  • A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients with Severe Sepsis (ACCESS) / EISAI / 2006-2010
  • Tifacogin in Severe CAP (CAPTIVATE), Study to Evaluate the Safety and Efficacy of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) Administration in Subject with Severe Community-Aquired Pneumonia / NOVARTIS / 2004-2008
  • Recombinant Platelet-Activating Factor Acetylhydrolase (rPAF-AH, Pafase) in severe sepsis / ICOS / 2001-2002

SLUCCC features

  • What is a Clinical Coordinating Center ?
  • Services during Studies
  • Real Time Resource

It is an academic group of physicians, study coordinators, research nurses and assistants distinct from the sponsor, who serve as the "real-time" main point of contact for the study sites

The Clinical Coordinating Center provide following services during studies :

  • 24/7/365 phone contact for all study sites
  • 100% Authorization of study subjects by a CCC Physician

Real Time Resource for sites regarding :

  • Protocol procedures
  • Study drug administration/device use
  • Concomitant medications
WIll Hill BookiesW.BetRoll here...
BetFair F.BetRoll UK Bookies